Abbvie INC ABBVIE ORD SHS
Abbvie INC ABBVIE ORD SHS/ US00287Y1091 /
0QCV
|
2024-04-17 5:45:40 PM
|
Chg.
-0.08
|
Volume |
Bid6:30:00 PM |
Ask6:30:00 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
163.28USD
|
-0.05%
|
22,046
Turnover: - |
-Bid Size: - |
-Ask Size: - |
290.14 bill.USD |
3.65% |
60.16 |
Business description
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
Management board & Supervisory board
| CEO |
| Richard A. Gonzalez |
| Management board |
| Scott T. Reents, Carrie Strom, Dr. Azita Saleki-Gerhardt, Jeffrey R. Stewart, Perry C. Siatis, Rae L. Livingston, Robert A. Michael, Timothy J. Richmond, Kevin Buckbee, Nicholas Donoghoe, Tracie Haas, Thomas Hudson, Greg Miley, Elaine K. Sorg |
| Supervisory board |
| Richard A. Gonzalez, Brett J. Hart, Edward J. Rapp, Frederick H. Waddell, Glenn F. Tilton, Melody B. Meyer, Rebecca B. Roberts, Robert J. Alpern, Roxanne S. Austin, Thomas Freyman, William H.L. Burnside |
Company data
| Name: |
AbbVie Inc. |
| Address: |
1 North Waukegan Road,North Chicago, Illinois 60064-6400, USA |
| Phone: |
+1-847-932-7900 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.abbvie.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
96.70% |
| IPO date: |
2013-01-02 |
Investor relations
| Name: |
Liz Shea |
| IR phone: |
+1-847-935-2211 |
| IR Fax: |
- |
| IR e-mail: |
liz.shea@abbvie.com
|
Company calendar
|
CW 17 | 2024-04-26
Interim Report 1st Quarter/3 Months
|
|
CW 20 | 2024-05-15
Dividend Payment
|
